1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Epiomic Epidemiology Series: Gout Forecast in 15 Major Markets 2015-2025

Epiomic Epidemiology Series: Gout Forecast in 15 Major Markets 2015-2025

  • September 2015
  • -
  • Black Swan Analysis Ltd132
  • -
  • 74 pages

Summary

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gout in 15 Major Markets
Gout is caused by the build up of uric acid in the joints due to the body producing too much or excreting too little in the urine, and develops into sodium urate crystals. The formation of these crystals causes pain and inflammation around bone joints. The majority of Gout attacks involve the first metatarsophalangeal joint (FMJ) which is the “big toe” (also known as podagra). Gout can also occur in other joints of the body such as the spine, other parts of the foot, hips or shoulders and hands.

This report provides the current prevalent population for Gout across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, Netherlands, Czech Republic, Greece, India and Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the frequency of Gout flares, joint involvement, kidney function and presence of tophi in Gout. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Gout have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Gout include:

-Obesity and weight gain
-Kidney stones, renal cysts and renal failure
-Coronary artery disease, Chronic Heart Failure
-Hypertension
-Dyslipidaemia
-Diabetes mellitus
-Metabolic syndrome
-Hyperuricaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global Gout’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of Gout and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Gout’s prevalent population.
-Identify sub-populations within Gout which require treatment.
-Gain an understanding of the specific markets that have the largest number of Gout patients.

Table Of Contents

Epiomic Epidemiology Series: Gout Forecast in 15 Major Markets 2015-2025
Gout
Table of Contents
-List of Tables and Figures
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography/Ethnicity
-Disease Prognosis andClinical Course
-Key Co-morbid Conditions /Features Associated with the Disease
-Methodology for Quantification of Patient Numbers
o Additional data available on request
-Top-Line Prevalence for Gout
-Features of Gout Patients Experiencing Flare in Past 12 Months
o Frequency of Flare in past 12 months
o Joint Involvement in Gout patients during Flare
o Kidney Function and Features in patients with Gout
-Features of Gout Patients at Initial Presentation
-Associated Co-morbid Conditions of Gout
-Tophaceous Gout
-Abbreviations used in the Report
-Other Black Swan Analysis Publications
-Black Swan Analysis Online Patient-Based Databases
-Patient-Based Offering
-Online Pricing Data and Platforms
-References
-Appendix


List of Figures
-ACR criteria for diagnosis of Gout
-ROME criteria for diagnosis of Gout
-New York criteria for diagnosis of Gout

List of Tables
-Prevalence of Gout, total (000s)
-Prevalence of Gout, males (000s)
-Prevalence of Gout, females (000s)
-Gout patients with at least one flare in the past 12 months, total (000s)
-Number of flares in past 12 months, total (000s)
-Location of affected joint in patients with Gout flare, total (000s)
-The extent of joint involvement in patients during Gout flare, total (000s)
-eGFR status of patients with Gout, total (000s)
-Prevalence of Renal Cysts in patients with Gout, total (000s)
-Prevalence of Nephrolithiasis in patients with Gout, total (000s)
-Estimated annual incidence of Gout, total (000s)
-Body Mass Index of patients with Gout at initial presentation, total (000s)
-Gout patients with a family history of Gout, total (000s)
-Uric acid level at presentation for patients with Gout, total (000s)
-Diabetes Mellitus in patients with Gout, total (000s)
-Dyslipidaemia in patients with Gout, total (000s)
-Prevalence of Hypertension in patients with Gout, total (000s)
-Hyperuricaemia in patients with Gout, total (000s)
-Metabolic Syndrome in patients with Gout, total (000s)
-Osteoarthritis in patients with Gout, total (000s)
-Peripheral Artery Disease in patients with Gout, total (000s)
-Presence of tophi in patients with Gout, total (000s)
-Patients with tophi by number present, total (000s)
-Abbreviations and Acronyms used in the report
-USA Prevalence of Gout by 5-yr age cohort, males (000s)
-USA Prevalence of Gout by 5-yr age cohort, females (000s)
-France Prevalence of Gout by 5-yr age cohort, males (000s)
-France Prevalence of Gout by 5-yr age cohort, females (000s)
-Germany Prevalence of Gout by 5-yr age cohort, males (000s)
-Germany Prevalence of Gout by 5-yr age cohort, females (000s)
-Italy Prevalence of Gout by 5-yr age cohort, males (000s)
-Italy Prevalence of Gout by 5-yr age cohort, females (000s)
-Spain Prevalence of Gout by 5-yr age cohort, males (000s)
-Spain Prevalence of Gout by 5-yr age cohort, females (000s)
-United Kingdom Prevalence of Gout by 5-yr age cohort, males (000s)
-United Kingdom Prevalence of Gout by 5-yr age cohort, females (000s)
-Brazil Prevalence of Gout by 5-yr age cohort, males (000s)
-Brazil Prevalence of Gout by 5-yr age cohort, females (000s)
-Japan Prevalence of Gout by 5-yr age cohort, males (000s)
-Japan Prevalence of Gout by 5-yr age cohort, females (000s)
-Canada Prevalence of Gout by 5-yr age cohort, males (000s)
-Canada Prevalence of Gout by 5-yr age cohort, females (000s)
-Australia Prevalence of Gout by 5-yr age cohort, males (000s)
-Australia Prevalence of Gout by 5-yr age cohort, females (000s)
-Netherlands Prevalence of Gout by 5-yr age cohort, males (000s)
-Netherlands Prevalence of Gout by 5-yr age cohort, females (000s)
-Czech Republic Prevalence of Gout by 5-yr age cohort, males (000s)
-Czech Republic Prevalence of Gout by 5-yr age cohort, females (000s)
-Greece Prevalence of Gout by 5-yr age cohort, males (000s)
-Greece Prevalence of Gout by 5-yr age cohort, females (000s)
-India Prevalence of Gout by 5-yr age cohort, males (000s)
-India Prevalence of Gout by 5-yr age cohort, females (000s)
-Mexico Prevalence of Gout by 5-yr age cohort, males (000s)
-Mexico Prevalence of Gout by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.